Dermata Therapeutics (DRMA) AI Stock Analysis

• Market Cap: $4.48M
• Dividend Yield: N/A
• Average Volume (3M): 134.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.15
• Revenue Growth: N/A
• EPS Growth: 75.68%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 6,378,118
• 10 Day Avg. Volume: 172,166
• 30 Day Avg. Volume: 134,821
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.50
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.43
• Enterprise Value/Market Cap: -1.17
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.54
• 1Y Price Target: $3.00
• Price Target Upside: 328.57% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 15 Underperform
• Price Target: ―

Dermata Therapeutics' stock is primarily impacted by its financial health, characterized by significant operating losses and reliance on external financing. Technical analysis indicates a bearish trend with potential overselling, while valuation remains difficult to assess due to negative earnings. These factors contribute to a low overall score.

Positive Factors

Clinical Trial Results

XYNGARI demonstrated statistically significant improvements over placebo as early as four weeks into treatment, highlighting its rapid efficacy.

Product Differentiation

XYNGARI's once-weekly application could improve patient adherence compared to currently FDA-approved topicals that require daily application.

Negative Factors

Financial Position

DRMA is pre-revenue and is expected to require a capital raise to fund ongoing operations and future trials.

Share Price Target

Based on expected share dilution from an anticipated capital raise, the 12-month price target is being lowered to $3.00, from $6.00.

Dermata Therapeutics Business Overview & Revenue Model

Company Description

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

How the Company Makes Money

Dermata Therapeutics primarily makes money through the development and licensing of its proprietary dermatology treatments. The company's revenue model includes securing partnerships with larger pharmaceutical companies for the co-development or commercialization of its drug candidates. Key revenue streams are expected to come from milestone payments, royalties on product sales, and licensing fees once their drugs receive regulatory approval and are brought to market. Additionally, the company may engage in research collaborations and receive funding support from grants or other financial partnerships to advance its pipeline.

Dermata Therapeutics Financial Statement Overview

Summary

Dermata Therapeutics is at a high-risk pre-revenue stage typical for biotech startups, with significant operating losses and negative cash flow. The absence of debt is a positive aspect, but the company's financial health is heavily reliant on external financing to sustain operations. Future financial stability hinges on developing revenue streams or securing continued financing.

Income Statement

Dermata Therapeutics has reported no revenue for the past several years, indicating a pre-revenue stage typical for biotech firms. The company has consistently recorded net losses, with a significant increase in net loss in 2024, reflecting ongoing operational challenges and substantial R&D expenses without offsetting revenues. This results in negative profitability metrics across all measured margins.

Balance Sheet

The company's balance sheet shows a reasonable equity position with no outstanding debt, which is positive for financial stability. However, the equity base has been declining, and total liabilities have increased over recent years. The equity ratio is declining, pointing to potential financial risk if this trend continues. The absence of revenue generation raises concerns about the sustainability of the current equity position.

Cash Flow

Operating cash flows are negative, consistent with the company's net loss position. Free cash flow is similarly negative, reflecting high cash burn typical of early-stage biotech firms. The company relies heavily on financing activities to fund operations, which may pose risks if external funding becomes challenging to secure.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	-322.00
EBITDA	-12.29M	247.22K	-9.67M	-7.86M	-3.17M
Net Income	-12.29B	-7.79M	-9.61M	-7.90M	-3.24M
Balance Sheet
Total Assets	3.53M	7.98M	6.94M	11.62M	605.45K
Cash, Cash Equivalents and Short-Term Investments	3.16M	7.44M	6.24M	10.80M	530.40K
Total Debt	0.00	0.00	0.00	0.00	3.55M
Total Liabilities	1.97M	1.62M	922.63K	1.52M	3.78M
Stockholders Equity	1.56B	6.36M	6.02M	10.11M	-28.08M
Cash Flow
Free Cash Flow	-11.16M	-6.41M	-8.83M	-5.69M	-4.03M
Operating Cash Flow	-11.16M	-6.41M	-8.83M	-5.69M	―
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	6.89M	7.61M	4.28M	15.96M	2.57M

Dermata Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DRMA, the sentiment is Neutral. The current price of 0.7 is above the 20-day moving average (MA) of 0.68, below the 50-day MA of 0.70, and below the 200-day MA of 1.05, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.33 is Neutral, neither overbought nor oversold. The STOCH value of 44.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DRMA.

Dermata Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	50 Neutral	AU$2.64B	3.32	-57.47%	2.62%	36.37%	14.48%
ADIL	32 Underperform	$8.11M	―	-217.01%	―	―	45.99%
MBIO	31 Underperform	$8.36M	―	270.52%	―	―	85.97%
AEON	24 Underperform	$8.92M	<0.01	13.29%	―	―	-261.69%
DRMA	15 Underperform	$4.48M	―	-206.26%	―	―	75.68%